Alzheimer’s Early
Intervention Inflammatory PanelInvestor Inquiry
Our vision is to shift the paradigm of Alzheimer’s detection upstream — giving
patients and clinicians the ability to intervene more effectively years earlier than current
technologies allow.
INVESTOR INQUIRIES
Join Moleculera Biosciences in our mission to improve the lives of those suffering from immune-mediated neuropsychiatric, cardiovascular and neurodegenerative disorders.
Investor inquiries please contact:
Craig Shimasaki, PhD, MBA President and CEO, Moleculera Biosciences shimasakic@moleculera.com
Gary Gentges Investor and Business Relations Consultant gentgesg@moleculera.com
If you would like us to contact you directly, please complete the form.